'Smart bombs' deliver kidney cancer medication

Researchers at the Society of Nuclear Medicine in San Antonio, TX, are zapping kidney cancer cells with "smart bombs" made of a new form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. The treatment is composed of medical radionuclides bound with antibodies that recognize physiological changes involved in the disease process. Once inside the body, the treatment targets cancerous tissues expressing the antigen carbonic anhydrase IX, which is associated with renal cell carcinoma. In a study, 14 of the 20 patients treated were able to reach stabilization of their cancer 12 weeks after treatment. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.